Ricardo Dolcetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7959414/publications.pdf

Version: 2024-02-01

313 papers

12,419 citations

28190 55 h-index 99 g-index

323 all docs 323 docs citations

times ranked

323

15447 citing authors

#	Article	IF	CITATIONS
1	Analysis of human leukocyte antigen associations in human papillomavirus–positive and –negative head and neck cancer: Comparison with cervical cancer. Cancer, 2022, 128, 1937-1947.	2.0	6
2	HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	1
3	B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation. Cancer Gene Therapy, 2021, 28, 649-666.	2.2	6
4	<i>PDCD1</i> and <i>IFNL4</i> genetic variants and risk of developing hepatitis C virusâ€related diseases. Liver International, 2021, 41, 133-149.	1.9	3
5	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.2	O
6	Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology, 2021, 10, 425.	1.3	6
7	Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. Molecular Therapy - Methods and Clinical Development, 2021, 21, 592-606.	1.8	11
8	Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches. Cancer Treatment Reviews, 2021, 98, 102219.	3.4	4
9	Abstract 1443: CHKing melanoma: CHK1 inhibitor +low dose hydroxyurea triggers immunogenic cell death and immunostimulatory cytokine expression to drive an anti-tumor immune response. , 2021, , .		O
10	Abstract 272: Glycomics: Protein glycosylation changes in the pathogenesis of head and neck cancer. , 2021, , .		0
11	Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers, 2021, 13, 3733.	1.7	12
12	Biological Predictors of De Novo Tumors in Solid Organ Transplanted Patients During Oncological Surveillance: Potential Role of Circulating TERT mRNA. Frontiers in Oncology, 2021, 11, 772348.	1.3	1
13	KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Frontiers in Immunology, 2021, 12, 791958.	2.2	2
14	Protein glycosylation in head and neck cancers: From diagnosis to treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188422.	3.3	13
15	Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?. Cancers, 2020, 12, 3392.	1.7	5
16	Enhancing chimeric antigen receptor Tâ€cell immunotherapy against cancer using a nanoemulsionâ€based vaccine targeting crossâ€presenting dendritic cells. Clinical and Translational Immunology, 2020, 9, e1157.	1.7	23
17	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. Hemato, 2020, 1, 10-22.	0.2	O
18	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. Hemato, 2020, 1, 5-6.	0.2	0

#	Article	IF	Citations
19	Scientifically based combination therapies with immunoâ€oncology checkpoint inhibitors. British Journal of Clinical Pharmacology, 2020, 86, 1711-1725.	1.1	6
20	Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area. Pathology and Oncology Research, 2020, 26, 2459-2467.	0.9	3
21	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 2020, 180, 895-914.e27.	13.5	127
22	Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors. Frontiers in Immunology, 2020, 11, 507.	2.2	5
23	Abstract B12: Examining EGFR-mediated PI3K/Akt pathway in combination therapy of cetuximab and dynamin inhibition. , 2020, , .		0
24	INTRANODAL TREATMENT WITH IFNÎ'-DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY. Hematological Oncology, 2019, 37, 317-318.	0.8	0
25	831 Bortezomib-induced immunogenic cell death enhances immune response in melanoma. Journal of Investigative Dermatology, 2019, 139, S143.	0.3	0
26	456 Bortezomib induces immunogenic cell death in melanoma and enhances immune responses in vivo. Journal of Investigative Dermatology, 2019, 139, S293.	0.3	0
27	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5231-5241.	3.2	34
28	Genetic and Epigenetic Mechanisms in Gastric Cancer. Current Clinical Pathology, 2019, , 25-40.	0.0	1
29	Immunomodulation and Immunotherapy for Gastric Cancer. Current Clinical Pathology, 2019, , 189-212.	0.0	1
30	NKT Cell–Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion. Cancer Immunology Research, 2019, 7, 952-962.	1.6	10
31	Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment. Cancer Medicine, 2019, 8, 3012-3016.	1.3	9
32	Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients. Frontiers in Oncology, 2019, 9, 160.	1.3	28
33	Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases. International Journal of Molecular Sciences, 2019, 20, 1280.	1.8	17
34	An ExÂVivo Human Tumor Assay Shows DistinctÂPatterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. Journal of Investigative Dermatology, 2019, 139, 213-223.	0.3	19
35	Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIVâ€infected patient. Hematological Oncology, 2019, 37, 176-184.	0.8	9
36	Prognostic Significance of Immune Microenvironmental Factors in Undifferentiated Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, e242.	0.4	0

#	Article	IF	CITATIONS
37	Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. Frontiers in Oncology, 2018, 8, 322.	1.3	137
38	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. International Journal of Molecular Sciences, 2018, 19, 1602.	1.8	48
39	Proposed Molecular and miRNA Classification of Gastric Cancer. International Journal of Molecular Sciences, 2018, 19, 1683.	1.8	64
40	Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. Journal of Clinical Investigation, 2018, 128, 1971-1984.	3.9	73
41	Abstract 1839: Suppression of Spry1 sensitizes cutaneous melanoma to BRAF-targeted therapy. , 2018, , .		0
42	High Response Rate in Relapsed/Refractory Follicular Lymphoma Following Personalised Immunotherapy with Intranodal IFN-Alfa-Dendritic-Cell and Rituximab. Blood, 2018, 132, 5334-5334.	0.6	0
43	Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis. Expert Review of Hematology, 2017, 10, 505-514.	1.0	23
44	A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors. Oncolmmunology, 2017, 6, e1304338.	2.1	13
45	A single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17. Scientific Reports, 2017, 7, 6555.	1.6	15
46	Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. Oncolmmunology, 2017, 6, e1356964.	2.1	42
47	Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. Clinical Epigenetics, 2017, 9, 58.	1.8	32
48	Predictive Value of FcR Polymorphisms. JAMA Oncology, 2017, 3, 342.	3.4	5
49	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
50	The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. International Journal of Cancer, 2017, 140, 1233-1245.	2.3	46
51	Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells. Frontiers in Immunology, 2017, 8, 197.	2.2	34
52	Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer. Frontiers in Immunology, 2017, 8, 1476.	2.2	54
53	Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study. Hereditary Cancer in Clinical Practice, 2017, 15, 16.	0.6	18
54	Teaching digital pathology: The international school of digital pathology and proposed syllabus. Journal of Pathology Informatics, 2017, 8, 27.	0.8	8

#	Article	IF	CITATIONS
55	Abstract 1196: Epigenetic drugs modulate long noncoding RNAs expression in BRAF inhibitor-resistant melanoma. , 2017, , .		O
56	In-depth analysis of compartmentalization of HIV-1 matrix protein p17 in PBMC and plasma. New Microbiologica, 2017, 40, 58-61.	0.1	2
57	Serologic investigation of undifferentiated nasopharyngeal carcinoma and simian virus 40 infection. Head and Neck, 2016, 38, 232-236.	0.9	13
58	Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells. Cell Death and Disease, 2016, 7, e2562-e2562.	2.7	36
59	Role of non-coding RNAs in resistance to targeted therapies in cutaneous melanoma. European Journal of Cancer, 2016, 69, S74.	1.3	0
60	Reverse immunoediting: When immunity is edited by antigen. Immunology Letters, 2016, 175, 16-20.	1.1	21
61	A lymphomagenic role for HIV beyond immune suppression?. Blood, 2016, 127, 1403-1409.	0.6	99
62	Role of the HIV matrix protein p17 in EBV-driven lymphomagenesis. European Journal of Cancer, 2016, 61, S67-S68.	1.3	0
63	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5 . 8	93
64	Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy. Cancer Immunology Research, 2016, 4, 431-440.	1.6	19
65	Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy. BMC Medical Genetics, 2016, 17, 11.	2.1	16
66	Toll-Like Receptor $1/2$ and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. PLoS ONE, 2016, 11, e0153823.	1.1	15
67	Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget, 2016, 7, 57327-57350.	0.8	24
68	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. Oncotarget, 2016, 7, 37487-37497.	0.8	16
69	Personalized Immunotherapy in Follicular Lymphoma By Intranodal IFN-Dendritic-Cell Combined to Anti-CD20 Antibody. Blood, 2016, 128, 2976-2976.	0.6	5
70	Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. Journal of Translational Medicine, 2015, 13, 204.	1.8	64
71	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
72	Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14331-14336.	3.3	58

#	Article	IF	Citations
73	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
74	Microenvironment and HIV-related lymphomagenesis. Seminars in Cancer Biology, 2015, 34, 52-57.	4.3	34
75	<i>FANCM</i> c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
76	Association of Type and Location of <i> BRCA1 < /i > and <i> BRCA2 < /i > Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.</i></i>	3.8	390
77	Cross-talk between Epstein-Barr virus and microenvironment in the pathogenesis of lymphomas. Seminars in Cancer Biology, 2015, 34, 58-69.	4.3	45
78	Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay. Clinical Epigenetics, 2015, 7, 89.	1.8	25
79	Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death and Disease, 2015, 6, e1774-e1774.	2.7	28
80	A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: Implications for EBV-driven lymphomagenesis in the HIV setting. International Journal of Cancer, 2015, 137, 1374-1385.	2.3	34
81	Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment. Cancer Letters, 2015, 369, 37-44.	3.2	118
82	Simian Immunodeficiency Virus and Human Immunodeficiency Virus Type 1 Matrix Proteins Specify Different Capabilities To Modulate B Cell Growth. Journal of Virology, 2014, 88, 5706-5717.	1.5	23
83	Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer, 2014, 14, 954.	1.1	9
84	Functional Avidity–Driven Activation-Induced Cell Death Shapes CTL Immunodominance. Journal of Immunology, 2014, 193, 4704-4711.	0.4	7
85	Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice. Journal of Translational Medicine, 2014, 12, 207.	1.8	8
86	Detection of HIV-1 Matrix Protein p17 Quasispecies Variants in Plasma of Chronic HIV-1–Infected Patients by Ultra-Deep Pyrosequencing. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 332-339.	0.9	8
87	A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity. Aids, 2014, 28, 2355-2364.	1.0	5
88	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
89	Stereotactic Ablative Radiation Therapy (SABR) for Oligometastatic Breast Cancer Patients: Investigating the Immune Profile to Identify Predictive Biomarkers. International Journal of Radiation Oncology Biology Physics, 2014, 90, S769.	0.4	O
90	Epstein-Barr virus and telomerase: from cell immortalization to therapy. Infectious Agents and Cancer, 2014, 9, 8.	1.2	11

#	Article	IF	Citations
91	157â€fPathogenesis of Epstein-Barr Virus-driven lymphomas of HIV+ patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 67.	0.9	О
92	High prevalence of Chlamydophila psittaci subclinical infection in Italian patients with Sjögren's syndrome and parotid gland marginal zone B-cell lymphoma of MALT-type. Clinical and Experimental Rheumatology, 2014, 32, 61-5.	0.4	16
93	Lymphomas occurring specifically in HIV-infected patients: From pathogenesis to pathology. Seminars in Cancer Biology, 2013, 23, 457-467.	4.3	102
94	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
95	Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. Seminars in Cancer Biology, 2013, 23, 441-456.	4.3	56
96	hTERT Inhibition Triggers Epstein–Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies. Clinical Cancer Research, 2013, 19, 2036-2047.	3.2	27
97	Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. Human Vaccines and Immunotherapeutics, 2013, 9, 1078-1083.	1.4	8
98	Breast Cancer and Simian Virus 40 Infection. Epidemiology, 2013, 24, 464-465.	1.2	12
99	Cancer, Aging and Immune Reconstitution. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1310-1324.	0.9	15
100	Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders. Clinical and Developmental Immunology, 2012, 2012, 1-19.	3.3	31
101	Virologic and Immunologic Evidence Supporting an Association between HHV-6 and Hashimoto's Thyroiditis. PLoS Pathogens, 2012, 8, e1002951.	2.1	121
102	IGKV3 Proteins as Candidate "Off-the-Shelf―Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas. Clinical Cancer Research, 2012, 18, 4080-4091.	3.2	14
103	Retinoic Acid/Alpha-Interferon Combination Inhibits Growth and Promotes Apoptosis in Mantle Cell Lymphoma through Akt-Dependent Modulation of Critical Targets. Cancer Research, 2012, 72, 1825-1835.	0.4	27
104	Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae. British Journal of Cancer, 2012, 106, 966-969.	2.9	13
105	Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation. Leukemia, 2012, 26, 814-821.	3.3	45
106	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1</i> /i>/ <i>2</i> (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
107	Detection of DNA of i>Chlamydophila psittaci / i>in subjects with psoriasis: a casual or a causal link?. British Journal of Dermatology, 2012, 167, 926-928.	1.4	9
108	Congenital cytomegalovirus infection: patterns of fetal brain damage. Clinical Microbiology and Infection, 2012, 18, E419-E427.	2.8	96

#	Article	IF	CITATIONS
109	<i>Chlamydophila Psittaci</i> Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial. Journal of Clinical Oncology, 2012, 30, 2988-2994.	0.8	167
110	210 Phospholipid Scramblase 1 Sensitizes Mantle Cell Lymphoma to Apoptosis Induced by Several Drugs. European Journal of Cancer, 2012, 48, S51.	1.3	0
111	936 The Interplay Between Telomerase and Epstein Barr Virus (EBV) –Silencing of HTERT Induces the EBV Lytic Cycle. European Journal of Cancer, 2012, 48, S225.	1.3	O
112	1084 Neoadjuvant Trastuzumab and Paclitaxel Combination Induces a High Rate of Pathological Complete Responses in Locally Advanced Breast Cancer by Exploiting Host Antitumor Immunity. European Journal of Cancer, 2012, 48, S261.	1.3	0
113	1085 Generation of EBV-specific CTL Lines Enriched in BARF1 Specificities for Improved Adoptive Immunotherapy of Nasopharyngeal Carcinoma. European Journal of Cancer, 2012, 48, S261.	1.3	0
114	1086 IGHV1-69 as a Promising Candidate for the Development of a Shared Immunotherapy to B-cell Lymphomas. European Journal of Cancer, 2012, 48, S261-S262.	1.3	0
115	Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Human Immunology, 2012, 73, 502-510.	1.2	41
116	Target therapy in elderly breast cancer patients. Critical Reviews in Oncology/Hematology, 2012, 83, 422-431.	2.0	6
117	NFATc2 Is a Potential Therapeutic Target in Human Melanoma. Journal of Investigative Dermatology, 2012, 132, 2652-2660.	0.3	41
118	Ocular Adnexal Lymphoma of MALT-Type and Its Association with Chlamydophila psittaci Infection. , 2012, , 139-163.		0
119	Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells. Cancer Immunology, Immunotherapy, 2012, 61, 881-892.	2.0	5
120	Prevalence of chlamydial infection in a series of 108 primary cutaneous lymphomas. British Journal of Dermatology, 2012, 166, 1121-1123.	1.4	7
121	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
122	Ovarian cancer susceptibility alleles and risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
123	Telomere/telomerase interplay in virusâ€driven and virusâ€independent lymphomagenesis: pathogenic and clinical implications. Medicinal Research Reviews, 2012, 32, 233-253.	5.0	30
124	Multiparametric Analyses of Human PBMCs Loaded Ex Vivo with a Candidate Idiotype Vaccine for HCV-Related Lymphoproliferative Disorders. PLoS ONE, 2012, 7, e44870.	1.1	4
125	Central nervous system marginal zone B-cell lymphoma associated with Chlamydophila psittaci infection. Human Pathology, 2011, 42, 738-742.	1.1	18
126	A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Research, 2011, 13, R117.	2.2	30

#	Article	IF	CITATIONS
127	Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives. Current Cancer Drug Targets, 2011, 11, 85-102.	0.8	27
128	Mood state profile and coping strategies after BRCA-1/2 genetic test disclosure: a retrospective study in Italy. Supportive Care in Cancer, 2011, 19, 733-735.	1.0	4
129	Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer. Cancer Immunology, Immunotherapy, 2011, 60, 1639-1645.	2.0	5
130	Immunotherapy for EBV-associated malignancies. International Journal of Hematology, 2011, 93, 281-293.	0.7	29
131	Common alleles at $6q25.1$ and $1p11.2$ are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, $2011, 20, 3304-3321$.	1.4	68
132	Prevalence of <i>Borrelia Burgdorferi</i> Infection in a Series of 98 Primary Cutaneous Lymphomas. Oncologist, 2011, 16, 1582-1588.	1.9	61
133	Immunologic profiling and clinical outcome in HER2+ breast cancer patients treated in a neoadjuvant phase II study: A step forward to understand trastuzumab activity Journal of Clinical Oncology, 2011, 29, e11083-e11083.	0.8	0
134	Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment (the) Tj ETQq	0 0 0 rgBT	·/Överlock 10
135	P3-14-25: Neoadjuvant Trastuzumab and Paclitaxel Combination Induces a High Rate of Pathological Complete Responses in Locally Advanced Breast Cancer by Exploiting Host Antitumor Immunity , 2011, , .		0
136	Chlamydophila psittaci subclinical infection in chronic polyarthritis. Clinical and Experimental Rheumatology, 2011, 29, 977-82.	0.4	6
137	The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica, 2010, 95, 1769-1777.	1.7	89
138	Genetic and epigenetic changes linked to <i>Chlamydophila psittaci</i> â€essociated ocular adnexal lymphomas. Hematological Oncology, 2010, 28, 1-2.	0.8	15
139	HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. Tissue Antigens, 2010, 75, 127-135.	1.0	22
140	Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors. Journal of Immunology, 2010, 184, 5895-5902.	0.4	43
141	Impact of \hat{I}^3 -chain cytokines on EBV-specific T cell cultures. Journal of Translational Medicine, 2010, 8, 121.	1.8	4
142	Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. Journal of Translational Medicine, 2010, 8, 18.	1.8	12
143	Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?. Infectious Agents and Cancer, 2010, 5, 22.	1.2	34
144	Unconventional therapies in ocular adnexal lymphomas. Expert Review of Anticancer Therapy, 2010, 10, 1341-1343.	1.1	2

#	Article	IF	Citations
145	Marginal zone B-cell lymphoma of the conjunctiva. Expert Review of Ophthalmology, 2010, 5, 177-188.	0.3	3
146	Role of CD4 ⁺ Cytotoxic T Lymphocytes in the Control of Viral Diseases and Cancer. International Reviews of Immunology, 2010, 29, 371-402.	1.5	47
147	A phase II trial addressing the prevalence of chlamydial infection and eradication efficacy of antibiotic therapy in marginal zone lymphoma (OAMZL) and other lymphoproliferative disorders of the ocular adnexae (LPDOA) Journal of Clinical Oncology, 2010, 28, e18520-e18520.	0.8	0
148	Characterization of Antibodies Directed against the Immunoglobulin Light κ Chain Variable Chain Region (VK) of Hepatitis C Virusâ€Related Typeâ€I Mixed Cryoglobulinemia and Bâ€Cell Proliferations. Annals of the New York Academy of Sciences, 2009, 1173, 152-160.	1.8	12
149	Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2009, 9, 113-131.	0.6	29
150	Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers. BMC Cancer, 2009, 9, 360.	1.1	3
151	Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes. International Journal of Cancer, 2009, 125, 1358-1364.	2.3	18
152	Chlamydial infection: the link with ocular adnexal lymphomas. Nature Reviews Clinical Oncology, 2009, 6, 658-669.	12.5	57
153	Degree of immune suppression and risk of HIV-related Hodgkin lymphoma: time points matter. Blood, 2009, 114, 2354-2354.	0.6	4
154	Bugs and marginal zone lymphoma of the ocular adnexae: is the future already here?. Blood, 2009, 114, 3499-3499.	0.6	3
155	<i>Chlamydophila psittaci</i> i>is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: Results of a singleâ€enter prospective case–control study. International Journal of Cancer, 2008, 123, 1089-1093.	2.3	66
156	Spontaneous T cell responses to Epsteinâ€Barr virusâ€encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. International Journal of Cancer, 2008, 123, 1100-1107.	2.3	32
157	Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opinion on Biological Therapy, 2008, 8, 1265-1294.	1.4	40
158	Latent Membrane Protein 1 of Epstein-Barr Virus Activates the hTERT Promoter and Enhances Telomerase Activity in B Lymphocytes. Journal of Virology, 2008, 82, 10175-10187.	1.5	65
159	Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Annals of Oncology, 2008, 19, 835-846.	0.6	93
160	Chlamydia psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma. Annals of Oncology, 2008, 19, 194-195.	0.6	38
161	GSK-3b inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. Cell Cycle, 2008, 7, 2813-2816.	1.3	42
162	Chlamydia Infection and Lymphomas: Association Beyond Ocular Adnexal Lymphomas Highlighted by Multiple Detection Methods. Clinical Cancer Research, 2008, 14, 5794-5800.	3.2	83

#	Article	IF	Citations
163	Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood, 2008, 111, 5142-5151.	0.6	142
164	Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?. Anti-Cancer Drugs, 2008, 19, 761-765.	0.7	37
165	HER2 guided neoadjuvant treatment of advanced breast cancer: Clinico-biological correlations. Journal of Clinical Oncology, 2008, 26, 11559-11559.	0.8	0
166	Immunoglobulin Gene Repertoire in Ocular Adnexa Lymphomas (OAL): Hints on the Nature of the Antigenic Stimulation. Blood, 2008, 112, 623-623.	0.6	0
167	Retinoic acid analogues inhibit human herpesvirus 8 replication. Antiviral Therapy, 2008, 13, 199-209.	0.6	12
168	Retinoic Acid Analogues Inhibit Human Herpesvirus 8 Replication. Antiviral Therapy, 2008, 13, 199-210.	0.6	17
169	Reply to the article â€~Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)' by P. Arnaud, MC. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369). Annals of Oncology, 2007, 18, 401-403.	0.6	5
170	Serum Antibody Response to Lytic and Latent Epstein-Barr Virus Antigens in Undifferentiated Nasopharyngeal Carcinoma Patients from an Area of Nonendemicity. Vaccine Journal, 2007, 14, 435-441.	3.2	10
171	A Woman and Her Canary: A Tale of Chlamydiae and Lymphomas. Journal of the National Cancer Institute, 2007, 99, 1418-1419.	3.0	30
172	Therapeutic management of ocular adnexal MALT lymphoma. Expert Opinion on Pharmacotherapy, 2007, 8, 1073-1083.	0.9	7
173	High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance. Infectious Agents and Cancer, 2007, 2, 5.	1.2	21
174	B-Cell Lymphomas Associated With HCV Infection. Gastroenterology, 2007, 132, 1205-1207.	0.6	21
175	Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. Digestive and Liver Disease, 2007, 39, S65-S71.	0.4	20
176	hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: Implications for EBV-driven lymphomagenesis. International Journal of Cancer, 2007, 121, 576-587.	2.3	33
177	Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells. Clinical and Experimental Immunology, 2007, 148, 402-409.	1.1	14
178	B lymphocytes and Epstein–Barr virus: The lesson of post-transplant lymphoproliferative disorders. Autoimmunity Reviews, 2007, 7, 96-101.	2.5	79
179	Role of the HLA Class II: HCV-Related Disorders. Annals of the New York Academy of Sciences, 2007, 1107, 308-318.	1.8	19
180	Protein Expression Profile of Celiac Disease Patient with Aberrant T Cell by Two-dimensional Difference Gel Electrophoresis. Annals of the New York Academy of Sciences, 2007, 1109, 429-440.	1.8	3

#	Article	IF	CITATIONS
181	Infectious Agents in Mucosa-Associated Lymphoid Tissue–Type Lymphomas: Pathogenic Role and Therapeutic Perspectives. Clinical Lymphoma and Myeloma, 2006, 6, 289-300.	1.4	39
182	Clinical value of Epstein–Barr virus DNA levels in peripheral blood samples of Italian patients with Undifferentiated Carcinoma of Nasopharyngeal Type. Cancer Letters, 2006, 233, 247-254.	3.2	37
183	Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunology, Immunotherapy, 2006, 55, 23-30.	2.0	63
184	Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer, 2006, 6, 156.	1.1	13
185	Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations. Genes Chromosomes and Cancer, 2006, 45, 791-797.	1.5	50
186	Association betweenHelicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications. Hematological Oncology, 2006, 24, 33-37.	0.8	48
187	Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Annals of Oncology, 2006, 17, 769-772.	0.6	71
188	Bacteria-Eradicating Therapy With Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial. Journal of the National Cancer Institute, 2006, 98, 1375-1382.	3.0	201
189	Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial. Annals of Oncology, 2006, 17, 1721-1722.	0.6	14
190	Re: Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas. Journal of the National Cancer Institute, 2006, 98, 365-366.	3.0	47
191	Proteomic Profile of Human Gut Biopsies from Celiac Patients with and without Severe Complications Blood, 2006, 108, 3899-3899.	0.6	0
192	Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins. Oncogene, 2005, 24, 2483-2494.	2.6	22
193	Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases. BMC Cancer, 2005, 5, 70.	1.1	73
194	Regression of Ocular Adnexal Lymphoma AfterChlamydia Psittaci–Eradicating Antibiotic Therapy. Journal of Clinical Oncology, 2005, 23, 5067-5073.	0.8	211
195	Latent Membrane Protein 1 Deletion Mutants Accumulate in Reed-Sternberg Cells of Human Immunodeficiency Virus-Related Hodgkin's Lymphoma. Journal of Virology, 2005, 79, 2643-2649.	1.5	14
196	EBV-Associated Tumors: Pathogenetic Insights for Improved Disease Monitoring and Treatment. Current Cancer Therapy Reviews, 2005, 1, 27-44.	0.2	11
197	Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Research, 2005, 65, 587-95.	0.4	33
198	Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica, 2005, 90, 1578-9.	1.7	67

#	Article	IF	Citations
199	Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas. Journal of the National Cancer Institute, 2004, 96, 586-594.	3.0	533
200	Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes. International Journal of Oncology, 2004, 25, 345.	1.4	1
201	Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles. Human Immunology, 2004, 65, 1397-1404.	1.2	26
202	Chlamydia Psittaci-Eradicating Antibiotic Therapy as a Potential Therapeutic Strategy Against Marginal Zone B-Cell Lymphoma of the Ocular Adnexa Blood, 2004, 104, 3274-3274.	0.6	1
203	Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes. International Journal of Oncology, 2004, 25, 345-55.	1.4	2
204	No association between polyomaviruses and primary central nervous system lymphomas of HIV-seronegative and HIV-positive patients. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1819-20.	1.1	2
205	Epstein-Barr virus: Induction and control of cell transformation. Journal of Cellular Physiology, 2003, 196, 207-218.	2.0	69
206	Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells. Oncogene, 2003, 22, 906-918.	2.6	7
207	Simian Virus 40 Sequences in Human Lymphoblastoid B-Cell Lines. Journal of Virology, 2003, 77, 1595-1597.	1.5	28
208	Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: New immunobiological and molecular insights on a long-standing etiopathogenic association. Advances in Cancer Research, 2003, 87, 127-157.	1.9	33
209	Ruolo del virus di Epstein-Barr nella patogenesi dei disordini linfoproliferativi post-trapianto. Microbiologia Medica, 2003, 18, .	0.3	1
210	Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: New immunobiological and molecular insights on a long-standing etiopathogenic association. Advances in Cancer Research, 2003, 87, 127-157.	1.9	10
211	Methylenetetrahydrofolate reductase 677 C->T polymorphism and risk of proximal colon cancer in north Italy. Clinical Cancer Research, 2003, 9, 743-8.	3.2	52
212	Isolated Bone Marrow Manifestation of HIV-Associated Hodgkin Lymphoma. Modern Pathology, 2002, 15, 1273-1278.	2.9	39
213	Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive or Both?. American Journal of Pathology, 2002, 160, 384-386.	1.9	1
214	Characterization of Epstein–Barr Virus Genotype in AIDS-Related Non-Hodgkin's Lymphoma. AIDS Research and Human Retroviruses, 2002, 18, 19-26.	0.5	16
215	Correspondence re: Samowitz et al., Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomark. Prev., 10: 917-923, 2001. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 499; author reply 499-500.	1.1	2
216	The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. Journal of Experimental and Clinical Cancer Research, 2002, 21, 115-24.	0.4	32

#	Article	IF	Citations
217	Microsatellite Instability and High Content of Activated Cytotoxic Lymphocytes Identify Colon Cancer Patients with a Favorable Prognosis. American Journal of Pathology, 2001, 159, 297-304.	1.9	275
218	Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. European Journal of Cancer, 2001, 37, 1276-1287.	1.3	81
219	What's New in the Biology and Treatment of Undifferentiated Carcinoma of Nasopharyngeal Type?. Acta Oto-Laryngologica, 2001, 121, 884-895.	0.3	8
220	Retinoic acid induces persistent, RAR?-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated c-myc oncogene but not in Burkitt's lymphoma cell lines., 2000, 86, 375-384.		21
221	Molecular profile of Epstein–Barr virus infection in HHV-8-positive primary effusion lymphoma. Leukemia, 2000, 14, 271-277.	3.3	60
222	Bidirectional induction of the cognate receptor-ligand $\hat{l}\pm4/VCAM-1$ pair defines a novel mechanism of tumor intravasation. Blood, 2000, 95, 2397-2406.	0.6	14
223	Glucocorticoids promote the proliferation and antagonize the retinoic acid–mediated growth suppression of Epstein-Barr virus–immortalized B lymphocytes. Blood, 2000, 96, 711-718.	0.6	13
224	Analysis and Significance of Anti-Latent Membrane Protein-1 Antibodies in the Sera of Patients with EBV-Associated Diseases. Journal of Immunology, 2000, 164, 2815-2822.	0.4	46
225	Elevated Serum Transforming Growth Factor \hat{I}^21 Levels in Epstein-Barr Virus-Associated Diseases and Their Correlation with Virus-Specific Immunoglobulin A (IgA) and IgM. Journal of Virology, 2000, 74, 2443-2446.	1.5	38
226	Glucocorticoids promote the proliferation and antagonize the retinoic acid–mediated growth suppression of Epstein-Barr virus–immortalized B lymphocytes. Blood, 2000, 96, 711-718.	0.6	3
227	Bidirectional induction of the cognate receptor-ligand $\hat{l}\pm4/VCAM-1$ pair defines a novel mechanism of tumor intravasation. Blood, 2000, 95, 2397-2406.	0.6	0
228	Bidirectional induction of the cognate receptor-ligand alpha4/VCAM-1 pair defines a novel mechanism of tumor intravasation. Blood, 2000, 95, 2397-406.	0.6	7
229	Glucocorticoids promote the proliferation and antagonize the retinoic acid-mediated growth suppression of Epstein-Barr virus-immortalized B lymphocytes. Blood, 2000, 96, 711-8.	0.6	3
230	Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease., 1999, 80, 240-249.		12
231	BRCA1 andBRCA2 genes: Role in hereditary breast and ovarian cancer in Italy. , 1999, 83, 5-9.		44
232	Activation of Infiltrating Cytotoxic T Lymphocytes and Lymphoma Cell Apoptotic Rates in Gastric MALT Lymphomas. American Journal of Pathology, 1999, 155, 823-829.	1.9	17
233	High Prevalence of Activated Intraepithelial Cytotoxic T Lymphocytes and Increased Neoplastic Cell Apoptosis in Colorectal Carcinomas with Microsatellite Instability. American Journal of Pathology, 1999, 154, 1805-1813.	1.9	425
234	T cell receptor repertoire in B cell lymphoproliferative lesions in primary Sj \tilde{A} ¶gren's syndrome. Journal of Rheumatology, 1999, 26, 1101-9.	1.0	5

#	Article	IF	CITATIONS
235	Lack of Fas and Fas-L mutations in patients with lymphoproliferative disorders associated with Sjögren's syndrome and type II mixed cryoglobulinemia. Clinical and Experimental Rheumatology, 1999, 17, 339-42.	0.4	5
236	Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G1 regulatory proteins: p27Kip1 up-regulation is a relevant early event. Oncogene, 1998, 17, 1827-1836.	2.6	32
237	The Epstein-Barr Virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases., 1998, 79, 481-486.		29
238	Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer. International Journal of Cancer, 1998, 78, 581-586.	2.3	24
239	Simian-virus-40 footprints in human lymphoproliferative disorders of HIVâ ⁻ and HIV+ patients. International Journal of Cancer, 1998, 78, 669-674.	2.3	75
240	Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Biomedicine and Pharmacotherapy, 1998, 52, 13-25.	2.5	14
241	<i>In Vitro</i> Effects of Retinoids on the Proliferation and Differentiation Features of Epstein-Barr Virus-Immortalized B Lymphocytes. Leukemia and Lymphoma, 1998, 29, 269-281.	0.6	5
242	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. Blood, 1997, 90, 776-782.	0.6	217
243	Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome. Arthritis and Rheumatism, 1997, 40, 318-331.	6.7	100
244	Epstein-Barr Virus Strains With Latent Membrane Protein-1 Deletions: Prevalence in the Italian Population and High Association With Human Immunodeficiency Virus–Related Hodgkin's Disease. Blood, 1997, 89, 1723-1731.	0.6	15
245	Epstein-Barr Virus Strains With Latent Membrane Protein-1 Deletions: Prevalence in the Italian Population and High Association With Human Immunodeficiency Virus–Related Hodgkin's Disease. Blood, 1997, 89, 1723-1731.	0.6	46
246	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. Blood, 1997, 90, 776-782.	0.6	23
247	Alpha 4 beta 7 integrin expression is associated with the leukemic evolution of human and murine T-cell lymphoblastic lymphomas. American Journal of Pathology, 1997, 150, 1595-605.	1.9	7
248	Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood, 1997, 89, 1723-31.	0.6	9
249	Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood, 1997, 90, 776-82.	0.6	45
250	Widespread clonal B-cell disorder in Sjogren's syndrome predisposing to Helicobacter pylori-related gastric lymphoma. Gastroenterology, 1996, 110, 1969-1974.	0.6	41
251	Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: A comparative study. Human Pathology, 1996, 27, 133-146.	1.1	56
252	Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus- immortalized B lymphocytes. Blood, 1996, 88, 3147-3159.	0.6	33

#	Article	IF	Citations
253	Human herpesvirus 6 in human immunodeficiency virus-infected individuals: Association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders., 1996, 48, 344-353.		25
254	B cell clonality in gastric lymphoid tissues of patients with Sjogren's syndrome Annals of the Rheumatic Diseases, 1996, 55, 311-316.	0.5	46
255	Human Herpesvirus 8 Is Present in the Lymphoid System of Healthy Persons and Can Reactivate in the Course of AIDS. Journal of Infectious Diseases, 1996, 173, 542-549.	1.9	159
256	Cellular and molecular bases of B-cell clonal expansions. Clinical and Experimental Rheumatology, 1996, 14 Suppl 14, S3-13.	0.4	10
257	The role of molecular analyses of B-cell and T-cell clonality in the study of B-cell lymphomagenesis. Clinical and Experimental Rheumatology, 1996, 14 Suppl 14, S21-9.	0.4	0
258	Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood, 1996, 88, 3147-59.	0.6	7
259	On the Biological Role of T-lymphocytes in T-cell-rich B-cell Lymphomas. American Journal of Clinical Pathology, 1995, 104, 231.1-231.	0.4	1
260	Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. Journal of Medical Virology, 1995, 45, 462-468.	2.5	108
261	Epstein-Barr virus-associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A. Arthritis and Rheumatism, 1995, 38, 867-868.	6.7	48
262	Characteristics of EBV-infected cells in HIV-related lymphadenopathy: Implications for the pathogenesis of EBV-associated and EBV-unrelated lymphomas of HIV-seropositive individuals. International Journal of Cancer, 1995, 63, 652-659.	2.3	23
263	Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood, 1995, 86, 1493-1501.	0.6	160
264	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood, 1995, 86, 1887-1892.	0.6	174
265	The Relevance of VDJ PCR Protocols in Detecting B-Cell Clonal Expansion in Lymphomas and Other Lymphoproliferative Disorders. Tumori, 1995, 81, 405-409.	0.6	17
266	Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors Journal of Clinical Oncology, 1995, 13, 1758-1767.	0.8	217
267	Genotypic and immunohistological demonstration of the progression of an unusual reactive-like B-cell lymphoproliferative disorder to a high grade diffuse lymphoma. Human Pathology, 1995, 26, 348-354.	1.1	2
268	Association of Epstein-Barr Virus with Hodgkin's Disease. Infectious Agents and Pathogenesis, 1995, , 375-393.	0.1	6
269	Association of Human Herpesvirus 6 with Human Tumors. Infectious Agents and Pathogenesis, 1995, , 313-326.	0.1	0
270	Can a specifically-aimed pathologic classification overcome the difficulties in defining HIV-associated lymphomas?. Pathologica, 1995, 87, 4-13.	1.3	1

#	Article	IF	Citations
271	Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease. Cancer Research, 1995, 55, 3675-81.	0.4	17
272	Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood, 1995, 86, 1493-501.	0.6	23
273	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood, 1995, 86, 1887-92.	0.6	36
274	Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. Journal of Rheumatology, 1995, 22, 1674-80.	1.0	26
275	The relevance of VDJ PCR protocols in detecting B-cell clonal expansion in lymphomas and other lymphoproliferative disorders. Tumori, 1995, 81, 405-9.	0.6	6
276	Human Herpesvirus 6: A Survey of Presence and Variant Distribution in Normal Peripheral Lymphocytes and Lymphoproliferative Disorders. Journal of Infectious Diseases, 1994, 170, 211-215.	1.9	121
277	In vivo phenotypic characteristics of AKR T-cell lymphomas with different leukemic potential: Possible role of $\hat{l}\pm4\hat{l}^27$ integrin in the progression towards the leukemic phenotype. International Journal of Cancer, 1994, 56, 560-567.	2.3	7
278	The epstein-barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in burkitt lymphoma lines. International Journal of Cancer, 1994, 57, 240-244.	2.3	132
279	Frequent detection of human herpesvirus 6 DNA in HIV-associated lymphadenopathy. Lancet, The, 1994, 344, 543.	6.3	11
280	The polymerase chain reaction detects B cell clonalities in patients with Sjögren's syndrome and suspected malignant lymphoma. Journal of Rheumatology, 1994, 21, 1497-501.	1.0	29
281	Polymerase chain reaction to assess B-cell clonality in clinical conditions at risk for B-cell malignancy. Transplantation Proceedings, 1994, 26, 3229-32.	0.3	2
282	High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large-cell ki-1-positive lymphomas in HIV-1-positive patients. International Journal of Cancer, 1993, 54, 53-59.	2.3	43
283	Subtypes of epstein-barr virus in HIV-1-associated and HIV-1-unrelated hodgkin's disease cases. International Journal of Cancer, 1993, 54, 895-898.	2.3	24
284	High-mobility-group (HMG) proteins and histone H1 subtypes expression in normal and tumor tissues of mouse. FEBS Journal, 1993, 213, 825-832.	0.2	53
285	Transformation-Associated Epstein-Barr Virus Antigens as Targets for Immune Attack. Annals of the New York Academy of Sciences, 1993, 690, 86-100.	1.8	9
286	HLA-All epitope loss isolates of Epstein-Barr virus from a highly All+ population. Science, 1993, 260, 98-100.	6.0	272
287	Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. British Journal of Cancer, 1993, 67, 674-679.	2.9	18
288	Type 2 Epstein-Barr Virus Genome and Latent Membrane Protein-1 Expression in a T-Cell-Rich Lymphoma of Probable B-Cell Lineage. American Journal of Clinical Pathology, 1993, 100, 541-549.	0.4	10

#	Article	IF	Citations
289	Association between B-type Epstein-Barr virus and Hodgkin's disease in immunocompromised patients [letter; comment]. Blood, 1993, 82, 328-330.	0.6	12
290	Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. Journal of Virology, 1993, 67, 1572-1578.	1.5	164
291	Demonstration of a unique Epstein-Barr virus-positive cellular clone in metachronous multiple localizations of Hodgkin's disease. American Journal of Pathology, 1993, 142, 33-8.	1.9	24
292	Association between B-type Epstein-Barr virus and Hodgkin's disease in immunocompromised patients. Blood, 1993, 82, 328-30.	0.6	5
293	Association of Epstein-Barr virus genome with mixed cellularity and cellular phase nodular sclerosis Hodgkin's disease subtypes. Annals of Oncology, 1992, 3, 307-310.	0.6	24
294	Pathogenesis of Human Reactive-Appearing «Non-Monomorphous» Malignant Lymphoproliferative Disorders: A Hypothesis. Tumori, 1992, 78, 221-227.	0.6	6
295	p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: Genetic and prognostic implications. International Journal of Cancer, 1992, 52, 178-182.	2.3	143
296	Adhesion molecule expression does not influence the leukemic behavior of murine T-cell lymphomas. Leukemia, 1992, 6 Suppl 3, 101S-105S.	3.3	1
297	Pathogenesis of human reactive-appearing "non-monomorphous" malignant lymphoproliferative disorders: a hypothesis. Tumori, 1992, 78, 221-7.	0.6	0
298	High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene, 1992, 7, 1159-66.	2.6	149
299	Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx. European Archives of Oto-Rhino-Laryngology, 1991, 248, 279-85.	0.8	9
300	Genotypic and Immunophenotypic Characterization of Two Human Light Chain– – Only B-Cell Non-Hodgkin's Lymphomas. American Journal of Clinical Pathology, 1990, 94, 390-396.	0.4	1
301	A coordinated proto-oncogene expression characterizes MCF 247 murine leukemia virus-induced T-cell lymphomas irrespectively of proviral insertion affecting myc loci. Leukemia Research, 1990, 14, 549-558.	0.4	5
302	Aids-related B-cell non-Hodgkin's lymphomas in direct blood-stream HIV-infected patients: Pathogenesis and differentiation features. International Journal of Cancer, 1990, 45, 883-888.	2.3	12
303	Establishment and characterization of a leukemic murine cell line derived from MCF 247 MuLV-induced T-cell lymphoma. International Journal of Cancer, 1990, 45, 928-934.	2.3	6
304	Pathogenesis of malignant lymphomas in intravenous drug-abuser, HIV-infected patients. Cancer Detection and Prevention, 1990, 14, 661-8.	2.1	1
305	Is the Epstein-Barr Virus Involved in Hodgkin's Disease?. Tumori, 1989, 75, 345-350.	0.6	32
306	N-myc activation by proviral insertion in MCF 247-induced murine T-cell lymphomas. Oncogene, 1989, 4, 1009-14.	2.6	21

#	Article	IF	CITATIONS
307	Is the Epstein-Barr virus involved in Hodgkin's disease?. Tumori, 1989, 75, 345-50.	0.6	10
308	Nuclear oncogene amplification or rearrangement is not involved in human colorectal malignancies. European Journal of Cancer & Clinical Oncology, 1988, 24, 1321-1328.	0.9	15
309	An Eco RI restriction length polymorphism at the murine L-myc locus. Nucleic Acids Research, 1988, 16, 11853-11853.	6.5	0
310	Activation by Point Mutation of Ki-ras Gene Occurring in Transfected Human Normal dna. Tumori, 1988, 74, 499-506.	0.6	0
311	Activation by point mutation of Ki-ras gene occurring in transfected human normal DNA. Tumori, 1988, 74, 499-506.	0.6	0
312	Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. Oncotarget, 0, 7, 41913-41928.	0.8	17
313	Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients. Frontiers in Oncology, 0, 12, .	1.3	1